期刊文献+

OLF方案联合HCPT腹腔灌注热化疗治疗胆系肿瘤疗效观察

The clinical effects in patients with biliary tract cancer treated with OLF combined with HCPT administrated as intraperitoneal perfusion hyperthermia
下载PDF
导出
摘要 目的:观察OLF[O:草酸铂(L-OHP);L:醛氢叶酸(LV);F:氟尿嘧啶(5-Fu)]方案联合羟基喜树碱(HCPT)腹腔灌注热化疗治疗晚期胆系肿瘤的近期疗效。方法:24例晚期胆系肿瘤患者采用OLF方案静脉化疗:L-OHP 85 mg/m2,CF 130 mg/m2静脉滴注2 h,第1、8天给药;5-Fu 200 mg/m2快速静脉滴注30 min,后给予5-Fu 1 000 mg/m2静脉泵入22 h,第1、8天给药。静脉化疗间歇期配合HCPT 15 mg腹腔灌注化疗,静脉化疗和腹腔化疗时均辅以热疗。28 d为1个周期,按RECIST评价疗效,同时综合评估临床受益反应指标:疼痛、体力状况及体重变化。结果:24例患者均化疗2个周期以上,其中完全缓解0例,部分缓解7例(29.2%),稳定8例(33.3%)。16例(66.7%)患者临床获益,生活质量提高。不良反应主要为骨髓抑制和消化道反应。结论:OLF方案联合HCPT腹腔灌注热化疗治疗晚期胆系肿瘤具有较好的近期疗效,不良反应能耐受,值得进一步研究。 Objective: To observe the clinical effects in patients with biliary tract cancer treated with OLF(L-OHP,LV,5-Fu) combined with hydroxycamptothecin(HCPT) which was administrated as intraperitoneal perfusion hyperthermia.Methods: Twenty-four patients were given chemotherapy as well as intraperitoneal chemotherapy combined with hyperthermia.The curative effects were estimated according the criterea of RECIST and the clinical benefit response rate(CBR) was evaluated.The CBR refers to pain,physical status and body weight.Results: There was no complete response among all the patients.Partial response was observed in 7 patients(29.2%) and stable disease was 33.3%.As to CBR,16 patients of total(66.7%) achieved the clinical benefit response and their quality of life was improved.The toxicities were marrow depression and alimentary tract reactions.Conclusion: This thermo-chemotherapy comprehensive regimen was an effective and safty methods for patients with advanced biliary tract cancer.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第11期1649-1652,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省教育厅自然科学基金(10KJB320008)
关键词 胆系肿瘤 化疗 腹腔灌注化疗 热疗 biliary tract cancer chemotherapy intraperitoneal perfusion chemotherapy hyperthermia
  • 相关文献

参考文献24

  • 1Rajagopalan V,Daines WP,Grossbard ML,et al. Gallbladder and bilitary tract carcinoma:A comprehensive update,part 1 [J]. Oncology (Huntingt),2004,18(8): 1049-1059.
  • 2Therasse P,Arbuck SG,Eisenhauer EA,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer.National Cancer Institute of the United States. National Cancer Institute of Canada [J]. J Nad Cancer Inst, 2000,92 (3) : 205-216.
  • 3Burris HA, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial [J]. J Clin Oncol, 1997,15 (6) :2403- 2413.
  • 4Ware LJ,Epps CD,Herr K,et al. Evaluation of the Revised Faces Pain Scale,Verbal Descriptor Scale,Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults[J]. Pain Manag Nurs,2006,7(5) : 117-125.
  • 5Furuse J,Okusaka T,Boku N,et al. S-1 mouotherapy as first-hne treatment in patients with advanced bihary tract cancer:a multicenter phase lI study [J]. Cancer Chemother Pharmacol, 2008,62(5) : 849-855.
  • 6Nehls O, Oett!e H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma:a prospective multicentre phase II trial [J]. Br J Cancer,2008,98(2): 309-315.
  • 7Kim YJ,Im SA,Kim HG,et al. A phase II trim of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer[J]. Ann 0ncol,2008,19(1):99-103.
  • 8Hong YS,Lee J,Lee SC,et al. Phase Ⅱ study of capecitabine and cisplatin in previously untreated ad- vanced biliary tract cancer [J]. Cancer Chemother Pharmacol, 2007,60 (3) : 321-328.
  • 9Andre T,Reyes-Vidal JM,Fartoux L,et al. Gemcitabine and oxaliplatin in advanced biliary tract earcinoma:a phase Ⅱ study[J]. Br J Cancer,2008,99(6):862-867.
  • 10Koeberle D,Saletti P,Borner M,et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemeitabine plus capecitabine:a muhicenter, phase Ⅱ trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol,2008,26(22) :3702-3708.

二级参考文献60

  • 1梅静峰,秦叔逵,刘秀峰,何泽明,吴成利,王琳.HELF方案联合干扰素治疗晚期胆囊癌的临床研究[J].临床肿瘤学杂志,2005,10(4):408-410. 被引量:8
  • 2Malik I A,Aziz Z.Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder[J].Am J Clin Oncol,2003,26 (2):124-126.
  • 3K.Kobayashi,A.Tsuji,S.Morita,et al.A phase Ⅱ study of 5-FU(CVI) and low-dose consecutive CDDP(LFP) therapy in advanced gallbladder carcinoma[C].ASCO Annual Meeting Proceedings,2005,23 (16s):372s.
  • 4Malka D,Boige V,Dromain C,et al.Biliary tract neoplasms:update 2003[J].Curr Opin Oncol,2004,16(4):364-371.
  • 5Rajagopalan V,Daines W P,Grossbard M L,et al.Gallbladder and biliary tract carcinoma:A comprehensive update,Part 1[J].Oncology (Huntingt),2004,18(7):889-896
  • 6Daines W P,Rajagopalan V,Grossbard M L,et al.Gallbladder and biliary tract carcinoma:A comprehensive update,Part 2[J].Oncology (Huntingt),2004,18(8):1049-1059.
  • 7Kubicka S.Cholangiocellular and gallbladder carcinoma[J].Z Gastroenterol,2004,42(5):397-402.
  • 8Scheithauer W.Review of gemcitabine in biliary tract carcinoma[J].Semin Oncol,2002,29(6 Suppl 20):40-45.
  • 9Park J S,Oh S Y,Kim S H,et al.Single-agent gemcitabine in the treatment of advanced biliary tract cancers:a phase Ⅱ study[J].Jpn J Clin Oncol,2005,35(2):68-73.
  • 10Tsavaris N,Kosmas C,Gouveris P,et al.Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer[J].Invest New Drugs,2004,22(2):193-198.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部